Dana-Farber tracks a variety of performance measures to assess
patient safety and quality of care, including our performance on
Joint Commission National Patient Safety Goals and various internal
The Leapfrog Group is a consortium of Fortune 500 companies
working to leverage improvements in health care quality and patient
safety. Since 2004, the group has surveyed U.S. hospitals on their
performance in four areas:
In 2008, the Leapfrog Group began asking hospitals to report
outcomes related to heart attacks and pneumonia, as well as the
incidence of hospital-acquired infections and injuries.
Dana-Farber supports the Leapfrog Group's efforts to promote
safe health care, and is pleased to participate in the Leapfrog
safety survey. The survey encourages transparency in health care by
providing consumers with information about safety practices at U.S.
As a specialty hospital focusing exclusively on cancer treatment
and research, some items in the survey do not apply to our
organization. For example, Dana-Farber neither operates an
intensive care unit, nor performs the high-risk surgeries. In
completing the survey, we applied materials provided by the
Leapfrog Group (and the National Quality Forum) to assess, as best
we could, our own safety practices. While we have exceeded Leapfrog
standards in many areas, we also identified several opportunities
to advance our ongoing efforts in teamwork training, communication
and feedback, and anticoagulation monitoring through this
For more information on Dana-Farber's Leapfrog survey
self-assessment, please contact Andrew Velasquez at email@example.com,
or at 617-582-8995.
See Dana-Farber's patient safety ratings on the Leapfrog Group Web site.
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free:
(866) 408-DFCI (3324)